Oral deucravacitinib benefits patients with lupus

Tyrosine kinases are enzymes that play central roles in signaling by cytokines involved in the pathogenesis of autoimmune diseases, including lupus. A recent phase 2 clinical trial published in Arthritis & Rheumatology has generated promising results for deucravacitinib, an oral inhibitor of tyrosine kinase 2 (TYK2), in patients with active lupus.

source https://medicalxpress.com/news/2022-11-oral-deucravacitinib-benefits-patients-lupus.html